RSS Subscribe to our Nanotechnology Business News feed

Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic

Calando Pharmaceuticals announced that the U.S. Food and Drug Administration has approved its investigational new drug application for lead anti-cancer compound, CALAA-01. The drug candidate is a targeted nanoparticle, comprised of a proprietary, non-chemically-modified siRNA against the M2 subunit of ribonucleotide reductase formulated with Calando?s proprietary RONDEL polymer delivery system.

Apr 22nd, 2008

Read more